Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saxon D Smith

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Dermatological Treatment|July 30, 2024
Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in AustraliaSaxon D Smith, Simon Fifer, Meredith Edwards, et al.
The Journal of Dermatological Treatment|March 29, 2017
Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid useSaxon D Smith, Lisa L Farrugia, Victoria Harris, et al.
Journal of the American Academy of Dermatology|February 25, 2020
Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumabSaxon D Smith, Curdin Conrad, Michael Ramharter, et al.
The Journal of Dermatological Treatment|April 18, 2020
Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12Alice B Gottlieb, Daniel Saure, Stefan Wilhelm, et al.
Dermatology and Therapy|June 23, 2023
Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical TrialsSaxon D Smith, Alexandros Stratigos, Matthias Augustin, et al.
The Journal of Dermatological Treatment|October 2, 2023
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeksAlexander Egeberg, Lars Erik Kristensen, Luis Puig, et al.
The Journal of Dermatological Treatment|March 1, 2021
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasisKristian Reich, Curdin Conrad, Lars Erik Kristensen, et al.
Dermatology Practical & Conceptual|June 1, 2022
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H TrialKristian Reich, Lars Erik Kristensen, Saxon D Smith, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)Andreas Pinter, Luis Puig, Knut Schäkel, et al.
The Australasian Journal of Dermatology|May 14, 2024
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patientsPeter Foley, Patrick D Mahar, Saxon D Smith, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Dermatological Treatment|July 30, 2024
Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in AustraliaSaxon D Smith, Simon Fifer, Meredith Edwards, et al.
The Journal of Dermatological Treatment|March 29, 2017
Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid useSaxon D Smith, Lisa L Farrugia, Victoria Harris, et al.
Journal of the American Academy of Dermatology|February 25, 2020
Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumabSaxon D Smith, Curdin Conrad, Michael Ramharter, et al.
The Journal of Dermatological Treatment|April 18, 2020
Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12Alice B Gottlieb, Daniel Saure, Stefan Wilhelm, et al.
Dermatology and Therapy|June 23, 2023
Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical TrialsSaxon D Smith, Alexandros Stratigos, Matthias Augustin, et al.
The Journal of Dermatological Treatment|October 2, 2023
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeksAlexander Egeberg, Lars Erik Kristensen, Luis Puig, et al.
The Journal of Dermatological Treatment|March 1, 2021
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasisKristian Reich, Curdin Conrad, Lars Erik Kristensen, et al.
Dermatology Practical & Conceptual|June 1, 2022
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H TrialKristian Reich, Lars Erik Kristensen, Saxon D Smith, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)Andreas Pinter, Luis Puig, Knut Schäkel, et al.
The Australasian Journal of Dermatology|May 14, 2024
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patientsPeter Foley, Patrick D Mahar, Saxon D Smith, et al.
Pageof 9